Indantadol
Alternative Names: CHF 3381; CMP 3381; CNP 3381; GT 3381; IL 0001; V 3881; V3381; V3381CCLatest Information Update: 09 Apr 2021
Price :
$50 *
At a glance
- Originator Chiesi Farmaceutici
- Developer Vernalis
- Class Amino acids; Analgesics; Antiepileptic drugs; Indans; Neuroprotectants; Small molecules
- Mechanism of Action Monoamine oxidase inhibitors; NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cough; Neuropathic pain
Most Recent Events
- 10 Oct 2018 Vernalis has been acquired by Ligand Pharmaceuticals
- 18 Nov 2010 Discontinued - Phase-II for Cough in United Kingdom (PO)
- 18 Nov 2010 Discontinued - Phase-II for Neuropathic pain in Canada (PO)